Skip to Content
Merck

Structural Basis for a Convergent Immune Response against Ebola Virus.

Cell host & microbe (2020-02-16)
Hadas Cohen-Dvashi, Matthias Zehner, Stefanie Ehrhardt, Michael Katz, Nadav Elad, Florian Klein, Ron Diskin
ABSTRACT

Ebola virus disease is a severe health problem in Africa. Vaccines that display the Zaire ebolavirus glycoprotein spike complex are a prime component for the effort to combat it. The VH3-15/Vλ1-40-based class of antibodies was recently discovered to be a common response in individuals who received the Ebola virus vaccines. These antibodies display attractive properties, and thus likely contribute to the efficacy of the vaccines. Here, we use cryo-EM to elucidate how three VH3-15/Vλ1-40 antibodies from different individuals target the virus and found a convergent mechanism against a partially conserved site on the spike complex. Our study rationalizes the selection of the VH3-15/Vλ1-40 germline genes for specifically targeting this site and highlights Ebolavirus species-specific sequence divergences that may restrict breadth of VH3-15/Vλ1-40-based humoral response. The results from this study could help develop improved immunization schemes and further enable the design of immunogens that would be efficacious against a broader set of Ebolavirus species.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Thermolysin from Geobacillus stearothermophilus, powder, BioReagent, 30-350 units/mg protein (E1%/280), suitable for cell culture
Sigma-Aldrich
Papain from papaya latex, lyophilized powder, ≥10 units/mg protein
Sigma-Aldrich
3,3′,5,5′-Tetramethylbenzidine (TMB) Liquid Substrate System for ELISA, peroxidase substrate